- Biodesix Named Company of the Year by Colorado BioScience Association
- AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study
- Biodesix Appoints Scott Hutton as Chief Executive Officer
Working alongside physicians, we solve complex diagnostic challenges from early diagnosis of lung nodules through late stage cancer.
We strive to improve every patient's lung cancer care by empowering physicians with swift, comprehensive, and actionable insights.
We focus on you and lung cancer. We are dedicated to providing all the answers you need by leveraging the best technology and options available.
Working alongside our biopharma partners, we boldly question the status quo and employ novel approaches to swiftly decipher the complexity of cancer. We provide our biopharma partners with end-to-end diagnostic solutions from initial biomarker discovery projects to companion diagnostic partnering, including commercialization and reimbursement.
Our team is dedicated to the scientific pursuit of solving the unsolvable and ultimately improving care for lung cancer patients.